University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Chancellor’s Honors Program Projects

Supervised Undergraduate Student Research
and Creative Work

Summer 8-2009

Role of Platelet Aggregation Inhibitors in Patients with Coronary
Artery Diseases
Dipti Kanaiyalal Chhajwani
University of Tennessee - Knoxville

Follow this and additional works at: https://trace.tennessee.edu/utk_chanhonoproj

Recommended Citation
Chhajwani, Dipti Kanaiyalal, "Role of Platelet Aggregation Inhibitors in Patients with Coronary Artery
Diseases" (2009). Chancellor’s Honors Program Projects.
https://trace.tennessee.edu/utk_chanhonoproj/1258

This is brought to you for free and open access by the Supervised Undergraduate Student Research and Creative
Work at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Chancellor’s
Honors Program Projects by an authorized administrator of TRACE: Tennessee Research and Creative Exchange.
For more information, please contact trace@utk.edu.

Role of Platelet Aggregation
Inhibitors in Patients with
Coronary Artery Diseases

Dipti Kanaiyalal Chhajwani
The University of Tennessee
College Scholars Program
Chancellor's Honors Program
Senior Thesis
July 2009

Mentor: Dr. Cynthia Peterson
Committee: Dr. Cynthia Peterson, Dr. Ana Kitazono, Dr. Phillip Daves

Abstract

Abciximab is a monoclonal antibody that is used as an intravenous
treatment to prevent platelet aggregation in patients undergoing
percutaneous
coronary
intervention.
Abciximab
acts
by
noncompetitively inhibiting the Glycoprotein lib/Ilia receptor by
binding to an allosteric site on the receptor. This inhibition prevents
fibrin from binding to the Glycoprotein lib/lila receptor, thus
preventing the final step of the platelet aggregation pathway. Two
drugs, Tirofiban and Eptifibatide, are also used as anti-platelet
aggregation treatment in patients undergoing percutaneous coronary
intervention and achieve similar results as Abciximab. However, the
mechanism of action is different, since Tirofiban and Eptifibatide are
small-molecule inhibitors that bind to the ligand binding site on the
Glycoprotein lib/Ilia receptors and serve as competitive inhibitors.
This thesis discusses the biochemical interaction of platelet
aggregation inhibitors within the platelet aggregation pathways of
patients undergoing percutaneous coronary intervention. Specific
biochemistry and clinical terms that relate to the platelet aggregation
inhibitors are presented in order to fully understand the mechanism of
action of the drugs.
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I. Introduction

Normally, the human body is in a state of equilibrium between factors that
prevent bleeding (pro-coagulant) and factors that prevent excessive blood
clotting (anti-coagulant). The hemostatic system enables a body to maintain the
vascular pathway by facilitating the formation and breakdown of blood clots. The
formation of blood clots (thrombi) within the blood vessel can be physiological
(contributing to normal bodily function) or pathological (disrupting function).
Pathological thrombus formation contributes greatly to overall morbidity and
mortality associated with heart diseases and is the center of ongoing research in
prevention and containment.

The Hemostatic System
Primary
Sevondary

Platellet Aggregation
Coagul,ation C,ascade'
Fibrinolysis

}

Formation of
blood clots

Breakdown of
blood clots

The blood coagulation cascade, known as secondary hemostatis, is
initiated by vascular damage. Blood coagulation has two pathways, intrinsic and
extrinsic. The overall goal of the cascade is to convert prothrombin into thrombin.
As seen in Figure 1, thrombin converts fibrinogen into fibrin. Fibrin then acts as a
ligand in the platelet aggregation pathway. Fibrin forms the insoluble mesh that
comprises the blood clot. The mesh is the substrate to which the platelets bind
and aggregate. The extrinsic and intrinsic pathways are comprised of a cascade
of reactions. The legend for Figure 1 describes the cascade leading to the
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Figure 1. Intrinsic and Extrinsic Coagulation Cascades
Intrinsic Pathway
Vascular Damage

Factor XI

Factor Xla

Factor IX

Factor lXa

Extrinsic Pathway
Dlsrupbon of Endothelium

Factor IX

Exposes Tissue Factor (TF)

Factor lXa

~
Factor VII

Factor VIa + Factor lXa

QB

~r-Factor X

TF + Factor VIa

TF + Factor VI

~
FactorXa

Thrombin

Prethrombin

~rFibrinogen

~
Fibrin

r--------------------------------------------------------------------------------The intrinsic pathway (yel/ow) begins with an initial vascular damage site which activates a
zymogen (inactive) factor XII into an active factor Xlla. The activated Glycoprotein factor
serves as a serine protease, cleaving the downstream zymogen at specific sites in order to
activate factor IX. The remaining steps of the intrinsic pathway function similarly until leading
to the common pathway (white) in which factor Xa binds to platelets to covert prothrombin into
thrombin. The extrinsic pathway (green) requires a tissue factor (TF) found on the
subendothelium, which in tum forms a complex with inactive factor VII to form active factor
Vila. The next step, in which the TF-factor Vila complex leads to the activation of factor X, is
essential. The activated factor Xa binds to platelets and leads to a common pathway that
converts prothrombin into thrombin.
Source: (Streiff 2001; Stassen, Arnout et al. 2004; Mackman, Tilley et al. 2007)
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common pathway that culminates in fibrin formation (Streiff 2001; Stassen,
Arnout et al. 2004; Mackman, Tilley et al. 2007).
Within the coagulation pathway, regulators, such as antithrombin, serve to
inhibit the effect of the serine proteases. This regulation prevents the activation of
the downstream zymogens into active factors. The procoagulant (such as the
activated factors shown in Figure 1) and the anticoagulant (such as antithrombin)
factors maintain the balance of the vascular system (Stassen, Arnout et al.
2004).
The tertiary component of the hemostatic system, fibrinolysis, regulates
the breakdown of the blood clots. This prevents occlusion of the vascular system
by the blood clots. Fibrinolysis occurs when plasminogen activators (present in
the endothelium) convert plasminogen into plasmin. Plasmin is the enzyme that
is responsible for the degradation of insoluble fibrin (Stassen, Arnout et al. 2004).
Fibrinolysis blocks platelets from adhering by disrupting the structure of fibrin.
Regulators of the fibrinolysis cycle, such as plasminogen activator inhibitor type 1
(PAI-1), a2-antiplasmin, a2-macroglobulin, and thrombin-activatable fibrinolysis
inhibitor, control the breakdown of fibrin clots by inhibiting fibrinolysis during
times of vascular injury when clotting is needed (Stassen, Arnout et al. 2004).
Platelet adhesion and aggregation, which are collectively termed primary
hemostatis, are important in formation of thrombi. At sites of vessel damage,
there is a propensity for platelets to aggregate and cause further arterial damage.
The mechanism responsible for platelet aggregation has been studied
extensively. The main components of the platelet aggregation pathway are the
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platelet stimulus (an agonist), a soluble adhesive protein (such as fibrinogen,
fibronectin, and the von Willebrand factor), and a membrane bound receptor on
platelets (the Glycoprotein lib/Ilia receptor) (Jackson 2007).
As Figure 2 depicts, the GP lib/lila receptor is found in the ligandunreceptive (inactive) state in resting platelets. Once an agonist, such as
adenosine diphosphate, thrombin, epinephrine, etc., acts as a stimulus to initiate
the platelet aggregation pathway, the GP IIb/llla receptor adopts a ligandreceptive (active) state. This activated state allows ligands to bind to the
receptor. Once enough GPllb/llla receptor ligands (such as fibrin, fibronectin,
and the von Willebrand factor) have attached to the GP II b/ilia receptor on the
platelet cell surface, the platelets are able to attach to one another creating a
chain of linked platelets (Winter and Juergens 2008). This platelet aggregation
and association with the fibrin mesh of the blood clot can continue until thrombus
formation is complete, causing the vessel to be blocked. Although the platelet
aggregation process is critical process for maintaining vascular integrity,
unchecked platelet aggregation can have serious pathological consequences.
The formation of atherosclerotic plaques is a common source of vessel
damage and can lead to unwarranted platelet aggregation. These plaques are
thickenings of the intima, the innermost layer of the artery (Hansson and Nilsson
2008). The effects of vessel damage can be intensified when individuals add to
the risks by engaging in activities that are deemed causes for heart disease.
Smoking, an unbalanced diet (which can lead to high cholesterol and diabetes),
and lack of physical exercise are considered to be risk factors for cardiovascular
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Figure 2. Platelet Aggregation Pathway
GP lib/Ilia
Receptor ligands

Platelet Aggregation

Figure 2 shows the platelet aggregation pathway. The ligand-unreceptive state, on
the left, is inactive. Once an external stimulus acts on the platelets, the receptor is
activated. The active state allows for ligand binding. When enough ligands have
attached to the GP lib/lila receptor on the platelet cell surface, the platelets are able
to attach to one another.
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diseases. With enough plaque formation, thrombi and arterial ruptures can create
pathological problems such as myocardial infarction (heart attack) and unstable
angina (chest pain) (Organization 2007).
Treatment of coronary artery diseases varies with severity. At times,
individuals are required to have surgical treatment (either elective or emergent).
There are many different surgical procedures that can be used to for patient
management. One such procedure is Percutaneous Coronary Intervention (PCI).
During a PCI procedure, occluded blood vessels are opened to restore blood
flow. Since the procedure introduces damage to the vessel, the platelet
aggregation pathway can be initiated. It is pertinent to use drug therapy
concurrently with PCI procedures to reduce the risk of platelet aggregation. As
Figure 3 shows, GP Ilb/liia receptor antagonists serve to inhibit the binding of the
GP IIb/llla receptor ligands by blocking or altering the active binding site on the
receptor. This receptor blockade prevents fibrinogen from binding to the GP
IIb/llla receptors, thereby preventing platelet aggregation.
This thesis will describe the biochemical interactions of platelet
aggregation inhibitors within the platelet aggregation pathways in patients
undergoing a PCI procedure. The paper will show the physiological responses
that these drugs elicit. The paper will compare and contrast the different
mechanism of action and development of the three main GP Ilb/liia inhibitor
drugs. The thesis focuses on one drug, Abciximab, and relates production and
mechanism of action of Abciximab to the related drugs, Tirofiban and Eptifibatide.
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Figure 3. Role of GP lib/lila Antagonists in the Platelet Aggregation Pathway

Occupied
Binding Site
GP lIb/IlIa
Receptor Inhibitors

Altered Conformation
State

---------------------------------------------------------------------------------1
GP lib/lila receptor antagonists serve to inhibit the binding of the GP lib/Ilia receptor
ligands by blocking or altering the active binding site on the receptor. This receptor
blockade prevents ligands from binding to the GP lib/lila receptors, thereby
preventing platelet aggregation.

:1
:
:1
:

______________________________________________________ - - - - - - - - - - - - - - - - - - - - - - ______ 1
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II. The Biochemistry that Governs Platelet Aggregation
In order to fully understand the scope of this paper, it is important to delve
into the biochemical mechanisms that regulate the formation and breakdown of
blood clots. In addition, a focus on the platelet aggregation process and the
proteins that regulate the process is also presented. Integrins are receptors on
the surface of cellular structures, such as platelets. Integrins are introduced here
since they play an important role in mediating platelet aggregation. Knowledge of
their structure and function is important in understanding the mechanisms that
the anti-platelet drugs carry out. The circulatory proteins, vitronectin and PAI-1
are discussed in Section III because of their role in the cardiovascular and
circulatory system during normal physiological activity and during pathological
events. The author of this thesis gained experience with these proteins during
laboratory work as an undergraduate researcher.

II-A. Integrin Receptors
The discovery of integrin receptors came from the need for scientists to
understand the adhesive interactions between cells and the extracellular matrix.
Integrins serve as receptors on the cell membrane. These integrin structures
span the entire cell membrane, forming a bidirectional control of cell adhesion.
Integrins bridge intracellular molecules of the cell to that of the extracellular
matrix or other cells through focal adhesion (Horwitz 1997). The binding of
ligands to integrin receptors allow signals to transverse from one location to
another.
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II-Ai. Structure
Integrins are composed of two distinct subunits, which are designated
alpha (0) and beta (B). Each subunit has a number of different variants. The
combination of 0 and

Bvariants create novel integrins. Some integrins are

specific to which type of ligand they bind to, whereas some are recognizable by
many ligand types (Horwitz 1997). Within each subunit, there is an extracellular
region, a transmembrane region, and an intracellular region. These regions are
outlined in Figure 4. According to sequence alignment of the human integrin
subunits, the transmembrane region is highly conserved in each of the 0 and

B

subunits (Lau, Kim et al. 2009). Figure 5 shows the transmembrane region of the
Glycoprotein lib/lila receptor and is a good representation of the transmembrane
region of a variety of integrins. Integrins are considered anthropomorphic
molecules, since they are composed of ligand-binding heads and two long legs.
Each subunit forms a leg, and both 0 and

Bsubunits combine to form the ligand-

binding head. The bent or non-bent configuration of the legs determine if the
integrin is in a low-affinity (which is its inactive state), high-affinity (which is at its
active state and ready to bind a ligand), or ligand-bound state (Mould and
Humphries 2004).
The role of integrins within the body has been studied heavily. Integrins
have been found to be involved in the signal transduction pathways that facilitate
proliferation, platelet aggregation, embryonic differentiation, inflammation, and a
host of other processes (Horwitz 1997).
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Figure 4. Integrin within the Cellular and Extra-cellular Matrix

1----------------------------------------------------------------------------------1
1: Figure 4 illustrates the placement of integrin structures within the cell.
1:
1______ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 1

- Chhajwani 16 -

Figure 5. Structure of the Glycoprotein lib/Ilia (allbP3) Transmembrane
Complex

r-----------------------------------------------------------------------Figure 5 shows the transmembrane structure of the Glycoprotein lib/ilia receptor.
The a subunit is colored red and the f3 subunit is colored blue. The N-terminal (at
the top) is the portion that is exposed to the extracellular matrix and the C-terminal
(at the bottom) is exposed to the cellular cytoplasm. The GP lib/ilia receptor
transmembrane region is stabilized by glycine residues (depicted as green/gray
structures in Figure 5). This stabilization is termed "glycine-packing".

Source: (Lau, Kim et al. 2009)
1_ _ _ _ _ _ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
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II-Aii. RGD Binding Site
In order to target specific integrins, researchers began to search for
binding sites on the receptors. There are numerous binding sites on receptors to
which ligands have a complementary structure. A known susceptible recognition
site on a ligand has been identified as the RGD (arginine-glycine-aspartic acid)
tripeptide binding site. It has been shown that numerous members of the integrin
family, including allbP3 and a v P3, recognize ligands that have the RGD motif.
RGD mimics can be used to alter physiological processes by blocking the ligandreceptor interaction site (Takagi 2004; Cini, Trabocchi et al. 2009).
Though the RGD motif is recognized by many integrins, there are also
other known binding sites. Even if an integrin sequence contains a RGD binding
site, there are secondary binding sites that can also offer selectivity. It has been
noted that the secondary sites interact with the a subunit of the integrin, whereas
the RGD motif interacts with the P subunit (Takagi 2004).

II-Aiii. Glycoprotein lib/Ilia Receptor (allbJ33 Integrin)
The integrin allbP3, also known as the Glycoprotein lib/Ilia receptor, is the
primary adhesion receptor of blood platelets within the body. The GP Ilb/liia
receptor is able to control platelet aggregation by binding to fibrin or other ligands
such as fibronectin and the von Willebrand factor (Lau, Kim et al. 2009). The GP
Ilb/liia receptor has an important role physiologically since it is involved in the
coagulation cascade/platelet aggregation pathway that forms the necessary
blood clots needed to maintain the vascular system. The GP Ilb/liia receptor has
an important role pathologically when excessive aggregation of platelets leads to
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thrombus formations. These thrombus formations can lead to myocardial
infarctions (heart attacks) or other adverse clinical presentations. The crystal
structure of the extracellular segment of the GP lib/lila receptor is shown in
Figure 6.
II-Aiv. The a v/33 Integrin

The integrin

av~3

is highly versatile and is an important receptor in tumor

angiogenesis and metastasis, inflammation, and bone resorption. The
integrin binds ligands with promiscuity. The integrin

av~3

av~3

is able to bind to a host

of ligands including vitronectin, angiostatin, and osteopontin. The

av~3

integrin

also serves as a receptor in viral processes that are attributed to the viruses that
cause foot-and-mouth disease, adenovirus, and human immunodeficiency virus.
The plethora of processes associated with the

av~3

integrin makes it an important

integrin to study. Researchers have solved a crystal structure for the

av~3

integrin. With this information, they hope to be able to further understand the
disease processes that the

av~3

integrin is associated with (Xiong, Stehle et al.

2001 ).
Researchers have solved a crystal structure of the 12

av~3

domains by

growing protein crystals. These crystals were then analyzed using single
isomorphous replacement-anomalous scattering and multiwave-Iength
anomalous diffraction technology to fully solve the structure. These 12 domains,
as seen in Figure 7, account for the extracellular segment of the integrin (Xiong,
Stehle et al. 2001).
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Figure 6. Crystal Structure of the Extracellular Domain of the GP lib/Ilia Receptor

. Head

Upper
Leg

Low
Leg

Figure 6 shows the crystal structure of the extracellular segment of the GP lib/ilia
receptor.
Source: (Zhu, Luo et al. 2008)
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Figure 7. Crystal Structure of the Extracellular Domain of the ovP31ntegrin

Stra ghtened

'::!I

EGF-3

532-562)
EGF-4
563~05)

~TD

(6 6- 90)

Figure 7 shows the crystal structure of the extracellular segment of the avf33Integrin. The a
subunit is shown in blue and the {33is shown in red. On the left is the ribbon drawing of the
structure and on the left is the straightened.
Source: (Xiong, Stehle et al. 2001)
1 _________________________________ _ _____ _ ________________________________________ _
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II-B. Circulatory Proteins: Vitronectin and PAI-1
In order for the body to maintain a careful biochemical balance, there are
numerous proteins that circulate. Two such proteins, Vitronectin and PAI-1, are
presented here in order to provide a snapshot of the role of circulatory proteins
that are involved in the hemostatic system. Vitronectin and PAI-1 are chosen for
this discussion because of the personal experience with the two proteins that the
author of this thesis has had during her undergraduate research.
II-Bi. Vitronectin
Vitronectin is a circulatory Glycoprotein that has a role in hemostatsis
through its regulation of blood coagulation (clotting) and fibrinolysis (break down
of blood clots). The 75 kDa protein plays an important role in cell adhesion,
differentiation, proliferation , and morphogenesis. Vitronectin is present in the
blood plasma at a concentration of about 200-400 ug/ml and accounts for about
.2-.5% of total plasma proteins (Preissner and Seiffert 1998; Ekmekci and
Ekmekci 2006). Circulating levels of Vitronectin are increased 2-3 fold in
pathological settings. Though Vitronectin is normally not present in most tissues,
Vitronectin accumulates at sites of injury or disease in tissues (Peterson 2009).
The domains of Vitronectin, depicted in Figure 8, enable binding of
Vitronectin to numerous partners. The 5MB domain contains the primary binding
site for PAI-1. Following the 5MB domain, there is the RGD sequence that
allows for binding to various integrins. The central domain could possibly contain
the binding site for self-association into multimers. The C-terminal domain
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Figure 8. The Domain Structure of Vitronectin

*

N----~----~--~-------------C
54130
1 1
131 323
5MB Domain

Centra Domain

c- terminal Domain

r------------------------------------------------------------------------ ----------Structures for the domains of Vitronectin are shown above the linear sequence. The three
domains for Vitronectin are termed the 5MB domain, the central domain, and the C-terminal
domain. The region between the 5MB domain and the central domain, depicted brown in Figure
!t is the disordered connection region. The blue "Y" structures on the linear sequence note the
sites of carbohydrate attachment.
Image Source: (Lynn, Heller et al. 2005)
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contains the heparin binding site and an alternate binding site for non-RGD
dependent integrins (Peterson 2009).
Experimentally, it has been shown that roles of vitronectin are dependent
on its conformational states. The monomeric form of vitronectin that is found in
circulation is soluble and binds to many partners. The partners for the monomeric
form include heparin, PAI-1, and numerous proteases. The oligomeric form of
vitronectin is the tissue-associated molecule that interacts with the extracellular
matrix and cell-surface receptors (such as the GP lib/lila receptor, the

av~3

integrin, and the uPA receptor) (Peterson 2009).
Vitronectin is recognized by a host of cell surface receptors, including the
Glycoprotein IIb/llla receptor and the

av~3

receptor. Its ability to be recognized by

various agents contributes to its function and importance within the cell.
Vitronectin is conserved between different species. Primary structure analysis
shows an 80% similarity between human, mouse, rat, rabbit, and porcine
sequences (Preissner and Seiffert 1998). The role of vitronectin in the hemostatic
system and restenosis are discussed in II-Bii. and iii.
II-Bii. PAI- 1 and the Role of the PAI-1Nitronectin Complex in the
Hemostatic System

Plasminogen Activator Inhibitor - type 1 (PAI-1) is a circulatory protein
involved in the regulation of vascular hemostatis. PAI-1 serves as a serine
protease inhibitor that inhibits the function of plasminogen activators such as
tissue plasminogen activator (tPA) and urokinase (uPA). By inhibiting tPA and
uPA, PAI-1 acts to inhibit the conversion of plasminogen to plasmin. This
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inhibition prevents fibrinolysis (tertiary hemostatis). Figure 9 shows the structural
conformation for active and latent (in-active) PAI-1.
PAI-1 is unstable, which causes the molecule to change from active to
latent form easily. Vitronectin forms complexes with PAI-1 and stabilizes PAI-1 in
an active conformation. The active PAI-1Nitronectin complex mediates stabilized
binding to fibrinogen. This complex impacts the thrombin-fibrinogen interactions
(Podor, Shaughnessy et al. 2000). Binding of PAI-1 to vitronectin may block
vitronectin from binding to other integrins or receptors, which initiate thrombus
formation. It has been shown that increased levels of PAI-1 in plasma levels are
associated with increased acute coronary syndromes (Ekmekci and Ekmekci
2006). The role of the PAI-1 and the PAI-1 Nitronetin Complex is shown in
Figure 10.
Along with mediating PAI-1 binding to fibrin, it has also been established
that Vitronectin interacts directly with the fibrin clots. The antithrombotic
interaction is carried out along the v-chains of fibrinogen and leads to vitronectinmediated inhibition of thombin-fibrinogen interactions (Podor, Campbell et al.
2002).
The role of Vitronectin in atherosclerosis is important. In the intimal
thickening, there are many layers of smooth muscle cells, monocyctes, Tlymphocytes, and cellular debris. Glycoproteins such as Vitronectin are found in
these atherosclerosis plaques because of their function within the extracellular
matrix. It has been observed that vitronectin can mediate the migration of smooth
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Figure 9. Active and Latent Forms of PAI-1

B

,------------------------------------------------------------------------------.
Figure 9 shows the active (A) and latent (B) forms of PAI-1 . The active form has the RCL,
reactive center loop, positioned in an exposed manor towards the targeted enzyme (the
serine proteases).
Image Source: (Stout, Graham et al. 2000)
1 ______ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 1
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Figure 10. Role of PAI-1 and Vitronectin in the Hemostatic System.
Normal Fibrinolysis
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Figure 10 shows the affect of PAI-1 and the PAI-1Nitronectin complex on fibrinolysis.
Normally, Plasminogen is converted to Plasmin. Plasmin breaks down the fibrin clots. PAI-1
and the PAI-1Nitronectin complex inhibit the fibrinolysis process. Vitronectin stabilizes PAI-1 ,
so the complex offers greater inhibition.
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muscle cells to these lesions via av~3/ av~5 integrin interactions, contributing to
thicker lesions (Ekmekci and Ekmekci 2006).
11-8iii. Role of Vitronectin in Restenosis

The role of the vitronectin receptor mediated migration of coronary smooth
muscle cells into the neointima (thickened layer of arterial lining) is important in
the process of restenosis. Restenosis refers to the narrowing of the blood
vessels. Vitronectin binding to the

av~3

integrin on the endothelial and smooth

muscle cells enables these cells to bind to the arterial lining and cause
vasoconstriction. Known antagonist treatments that are effective in inhibiting the
GP II b/llla receptor function are not effective for inhibiting the

av~3integrin

from

carrying out its function. However, novel treatments using biphenyls are showing
promise (Urbahns, Harter et al. 2002).
III. Focus of the Research Program Led by Dr. Cynthia Peterson at
University of Tennessee
In order to understand complex physiological processes, researchers from
all over the world team up to understand the role of particular units, for example,
proteins. In this collaborative model, each principal investigator and their
corresponding research group have a vital role to play in understanding the entire
process by focusing on one particular issue at a time.
III-A. Peterson Lab Group
The Peterson Lab at the University of Tennessee is one such group. This
group's main focus is to understand the function and structure of vitronectin (and
the proteins that vitronectin forms complexes with). Vitronectin is known to form
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complexes with numerous molecules in circulation and in the extracellular matrix.
One such molecule is PAI-1. As stated in a grant submitted to the National
Institute of Health , a central hypothesis of the Peterson group is to show the
interactions of PAI-1 and vitronectin; and , the effects of those interactions on
structure, function , and tissue localization of the proteins (Peterson 2009). The
Peterson group has contributed greatly to the study of the hemostatic system by
determining the role that the stability of the PAI-1Nitronectin complex has in
increasing inhibition of plasminogen activators. The Peterson group has further
contributed to the study of the hemostatic system by interpreting the interactions
of vitronectin to fibrin clots.
Another aim of the Peterson group is to use new biochemistry
technologies, such as small angle neutron scattering, high-end tandem mass
spectrometry, and high-resolution cryo-electron microscopy, to further advance
knowledge of complex formations. University of Tennessee's proximity and
relations to Oak Ridge National Laboratory makes it feasible to study these
cases in detail (Peterson 2009).
The specific focuses of study of the Peterson group are to determine the
exact sites on Vitronectin that PAI-1 binds to; how binding alters their
conformation; and the architecture and subunit composition of the complexes. By
learning more about these topics , the group hopes to relate the findings to a
whole host of physiologically important topics. Since both vitronectin and PAI-1
are immensely important in thrombus formation and atherosclerosis, the findings
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of the Peterson group can contribute to researching novel prevention and
containment protocols (Peterson 2009).

III-B. Undergraduate Research Experience of Dipti Chhajwani
Since 2006, the author of this senior thesis, Dipti Chhajwani, has been a
part of Dr. Cynthia Peterson research group. As an undergraduate researcher,
Dipti was exposed to protein biochemistry research at the start of her sophomore
year. Being a part of a large scale research group, Dipti was allowed to interact
with and learn from advanced biochemists. Her early exposure to scientific
technique and thought process will be invaluable to her future career.
Dipti started her own research project during the summer of 2008. Since
vitronectin is comprised of 459 residues (amino acids), the project goal was to
isolate eight 100 amino acid peptides, (position 1 - position 100; 51-150; 101200; 151-250; 201-300; 251-350; 301-400; 351-459). The sequences for the
amino acids for the eight recombinant peptides of Vitronectin were cloned into
the pET15b expression vector system. Through DNA purification and sequence
analysis, Dipti ensured that the correct Vitronectin DNA was present. In order to
achieve protein expression at a higher scale, it was beneficial to transform the
peptides in an E. coli host strain, Rosetta 2(OE3). The Rosetta strain was chosen
for the transformations because of the Peterson group's experience with the
strain. The Rosetta strain allows for enhanced inducible expression of peptides
within the pET plasmid. Once transformation was complete, Dipti began smallscale induction of the cells. However, due to complications in technique and
within the cell line, expression was not achieved at a high scale.
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The overall goal of the project was to isolate the eight 100 amino acid
peptides to perform binding studies to test for self oligomerization of vitronectin
and to study the second binding site for PAI-1.
IV. Background on Cardiovascular Diseases with a Focus on Coronary
Artery Diseases
In order to understand the clinical background of patients who are given
anti-platelet aggregation treatment during percutaneous coronary intervention,
this thesis gives a background on Cardiovascular Diseases and Coronary Artery
Diseases. Also, treatments of coronary artery disease are introduced, along with
the complications that arise during/after treatment.
IV-A. Cardiovascular Diseases
Cardiovascular diseases are considered to be the number one cause of
mortality globally. In the United States in 2006, 80 Million (comprising of 36.3% of
the population) adults over the age of 20 had at least one form of Cardiovascular
Disease (Association 2009). Cardiovascular diseases are disorders of the heart
and blood vessels. There are a variety of different types of Cardiovascular
Diseases, including Coronary Artery Disease, Cerebrovascular Disease,
Peripheral Arterial Diseases, Rheumatic Heart Disease, and Congenital Heart
Disease (Organization 2007). Table 1 gives the conditions of each of these types
of cardiovascular diseases along with their clinical presentations.
The World Health Organization publishes literature yearly that focuses on
prevention of cardiovascular diseases. Causes of these diseases are well known
and can be preventable. The majority of causes of heart disease and stroke arise
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Table 1. Types of Cardiovascular Diseases
Source: (Organization 2007; Association 2009)
Coronary Heart
Disease

Cerebrovascular
Disease
Peripheral Arterial
Disease
Rheumatic Heart
Disease

Congenital Heart
Disease

Deep Vein
Thrombosis;
Pulmonary Embolism

Condition/ Clinical Presentation
Diseases of the blood vessels that supply the heart
muscle.
Examples: Myocardial Infarction (Heart Attack); Unstable
Angina (Chest Pains)
Diseases of the blood vessels that supply the brain.
Example: Stroke
Diseases of the blood vessels that supply the arms and
legs.
Examples: Ischemia (restriction of blood supply)
Disease that presents as damage to the heart muscle and
heart valves.
Caused by Streptococcal bacteria, which leads to
Rheumatic Fever.
Conditions or Malformations of heart structures that are
existing at birth.
May be caused during gestation or by genetic factors.
Examples: Abnormal valves/chambers; Holes in the heart
Present as blood clots in the leg veins. These clots can
cause further damage by dislodging and moving to the
heart and lungs.
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from modifiable risk factors. Though the process is complex and involves genetic
predispositions, there are several risk factors. Modifiable risk factors such as
smoking, hypertension (high blood pressure), high cholesterol, and diabetes
contribute to heart disease (Organization 2007). Disease awareness plays an
important role in disease prevention. Various professional organizations such as
the World Health Organization and the American Heart Association have
developed marketing plans to inform the public of the dangers of an unbalanced
lifestyle on health (Association 2009). This was exemplified by the statistics
gathered in 2006 that showed that 570/0 of women surveyed knew that heart
disease is the leading cause of death in women. Similar surveys conducted in
previous years showed that fewer women knew of the significance of heart
disease. In 2003, 46% of women surveyed knew that heart disease is the leading
cause of death in women. This can be further traced back to 1997 and 2000,
when the figures were only 300/0 and 34%, respectively (Christian, Rosamond et
al.2007).
IV-B. Coronary Artery Diseases
In 2006, an estimated 16.8 million Americans suffered with Coronary
Artery Diseases (Association 2009). Coronary artery disease is primarily caused
by atherosclerotic lesions. These lesions are thickenings of the innermost layer of
the artery, known as the intimal lining. These thickenings consist of cells,
connective-tissue elements, lipids, and cellular debris. Often times, inflammatory
and immune cells are found in these lesions as well as vascular endothelial and
smooth muscle cells (Hansson and Nilsson 2008).
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Pre-lesion materials called fatty streaks are present prior to an actual
formation of an atherosclerotic lesion. These fatty streaks can eventually
disappear or develop into larger units. Once an atherosclerotic lesion forms with
enough depth, that it is able to block blood flow through the coronary arteries, a
thrombus site is created, which can possibly rupture (Hansson and Nilsson
2008). Figure 11 shows the cross sectional view of a thrombus site that led to a
myocardial infarction.

IV-Bi. Types of Coronary Artery Diseases
There are several types of coronary heart diseases. These conditions can
range from mild discomfort to acute attacks that require medical attention.
Myocardial infarctions ("heart attacks") are recognized to be one of the
leading causes of death and disability worldwide. Patients with coronary
atherosclerosis have periods of instability and stability. During times of instability,
when inflammation in the vascular walls is activated, patients are prone to
develop myocardial infarctions. Myocardial infarctions are pathological conditions
of damage to the cardiac muscle, which can lead to necrosis (cell death or
rupture). Myocardial infarctions can be detected clinically through rise or fall of
specific biomarker concentrations present in the blood stream and through
electrocardiograms (Thygesen, Alpert et al. 2007).
Angina is a condition where patients experience chest pain or discomfort
when there is a lack of blood flow to the heart. Patients who have severe angina,
termed unstable angina, complain of pains throughout resting periods and
require immediate medical attention.
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Figure 11. Thrombus Formation Leading to Ruptures

r---------------------------------------------------------------------------------.

Figure 11 shows atherosclerotic lesions within a human artery. The thrombus site occludes
•
the artery, and one can see the rupture of the thrombus between the arrows. The rupture
exposes the contained debris within the thrombus to cellular environment. This shows a cross
sectional view of a coronary artery of a patient who died of a myocardial infarction.
Source: Dr. Erling Falk, University of Aarhus, Aarhus, Denmark; (Hansson and Nilsson 2008)
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IV-Bii. Treatment
Various types of treatment for coronary artery disease have been utilized
for decades. Cardiologists often choose to place patients on medications that
reduce blood clot formations, such as Clopidogrel or Aspirin. If the condition
worsens, then elective or emergent procedures must be carried out. There are
two well known surgical procedures that are documented. Coronary-artery
bypass grafting (CABG) is one such procedure. CABG is a procedure in which
blood is rerouted around the blocked coronary artery by a transplanted piece of
vessel, known as a graft. The CABG procedure was introduced in 1968. Through
further advances in surgical techniques, CABG has grown to be one of the
surgical standards for patients presenting with coronary artery disease (Serruys,
Morice et al. 2009).
Another type of surgical procedure, PCI, was introduced in 1977 (Smith,
Dove et al. 2001). It has been noted that an estimated 1.3 million PCI procedures
were performed in the United Stated in 2006 (Association 2009). This procedure
allows surgeons to place stents via catheterization at sites of thrombus formation.
PCI procedures have enabled treatment of complex lesions in patients with
advanced coronary artery disease, coexisting conditions, or anatomical risk
factors (Smith, Dove et al. 2001). The main goal of a PCI is to open a clogged
coronary artery and restore blood flow.
As depicted in Figure 12, the surgeon gains access to the heart and major
blood vessels through a femoral artery in the groin or radial artery in the forearm.
Once the artery is punctured using a special needle, x-ray technology allows a
catheter to be threaded up into the aorta. The needle is then finally advanced to
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Figure 12. Percutaneous Coronary Intervention Procedure

Blocked Coronary Artery

Restoration of Blood Flow

1----------------------------------------------------------------------------------1
: This illustration shows how a catheter is inserted into the femoral artery and then threaded up
: to the site of vascular injury. After the insertion of a stent via balloon angioplasty, restoration
:1 of blood flow occurs.
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the sight of thrombus formation. Once the catheter reaches its destination, a
balloon is inflated to open up the artery. Often times, a stent, which is a mesh-like
metal tube, is left behind to serve as a scaffold and uphold the restoration of
blood flow (Torpy, Lynm et al. 2004).

V-Biii. Complications in Treatment
A common complication arising during PCI procedures is excessive
bleeding due to anti-coagulants. This problem needs to be dealt with
immediately. It has been shown that increased bleeding can lead to increased
mortality if correct remedies, such as blood transfusion, are not taken. The type
of vascular access strategy (whether the femoral or radial artery is accessed)
combined with which antithrombotic agent is used, does affect patient outcome.
Combined studies are being performed to determine which methods result in the
most beneficial outcome for patients (Doyle, Rihal et al. 2009).
Another complication that can arise after PCI is formation of intracoronary
thrombus sites. Since a surgical procedure introduces foreign substances to a
vessel wall, the damage causes the activation of the platelet aggregation
pathway. As Figure 13 depicts, these thrombus sites occur close to intracoronary
guide wire and cause increased vasoconstriction. To combat these issues, antiplatelet agents are often used in conjunction with PCI (Zeiher, Schachinger et al.
1991 ).
Another complication that can arise after PCI is re-blockage of the treated blood
vessel, known as restenosis. Restenosis usually occurs within six months of the
PCI procedure. Restenosis occurs more often in patients who had a
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Figure 13. Post Stent Placement Thrombus Formation

r----------------------------------------------------- ----------------------------~

This angiogram shows vasoconstriction response due to thrombus formation post angioplasty.
Part A shows the vessel post angioplasty, one can still see the guide wire introduced during
the procedure (circled red). Part B shows the formation of a thrombus site along the side of
the vessel wall, near the guide wire (denoted by the red arrow). Part C shows the
vasoconstriction experienced post thrombus formation (white arrows).
Source: (Zeiher, Schachinger et al. 1991)
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balloon angioplasty without stent placement. Stent placement has become the
norm for angioplasty procedures. When there is restenosis post stent placement,
it is referred to as in-stent restenosis. Normally, a patient grows healthy tissue
inside and around the stent to create a smoother and more natural flow process
for the blood. Approximately 25% of patients post stent placements have some
form of scar tissue that forms around the stent. However, as Figure 14 shows, if
thick scar tissue forms, the lining of the artery can become clogged and obstruct
blood. If a patient presents no signs of in-stent restenosis within 12 months of a
PCI procedure, the condition becomes rare. Prevention methods for restenosis
are started the day of the surgery. Complications can be reduced if the surgeon
places the stent appropriately via use of additional technology or expertise.
Drugs and vitamins are being studied to determine their efficiency in reducing
restenosis when used during PCI (Dangas and Kuepper 2002).
V. Strategies in Combating Complications from PCI Procedures
There are various classifications of drugs that serve to block receptors.
The three major types are agonist, antagonist, and inverse agonist. A drug that is
considered an agonist, binds to a receptor. In doing so, it alters the normal
activity of the receptor. An inverse agonist serves to have an opposite effect as
that of the agonist. An antagonist also binds to a receptor, but does not alter the
normal activity of the receptor. An antagonist hinders the effects of agonists and
inverse agonists. Receptors can be activated by their respective ligands (which
serve as agonists) or by pharmaceutically produced agonists (Negus 2006).
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Figure 14. In-stent Restenosis

Restoration of Blood Flow
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Scar tissue for'm ation ,a round stent .s ite

1---------------------------------------------------------------------------------,
: Figure• 14 illustrates the formation of thick scar tissue post stent placement. This
: scarrmg blocks blood flow.
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The actual site on the receptor that the drugs target is also a characteristic
of the drug. Since cell surface receptors are heavily targeted by 600/0 of current
drugs, understanding these interactions are crucial to develop effective drugs.
There are two types of binding sites. One is an orthosteric site, which is the site
where the actual ligand binds to the receptor. Traditionally, most drugs actively
seek to bind to the orthosteric site. All types of drug types (agonist, antagonist,
and inverse agonist) can recognize the domain. These drugs bind competitively
and hinder the original ligand from binding to the receptor. Recent developments
are showing that drugs can indeed bind at an allosteric binding site. This site is
not the ligand binding site and can be located near or far from the original agonist
binding site. The drugs that bind to allosteric sites can be competitive or noncompetitive (Christopoulos 2002).
The Glycoprotein lib/lila receptor inhibitors, Abciximab, Tirofiban, and
Eptifibatide, act as antagonists to prevent fibrin from binding to the receptor. As
Figure 15 shows, Abciximab binds to an allosteric site, altering the conformation
of the receptor, thus preventing fibrin binding to the receptor. Eptifibatide and
Tirofiban bind to the orthosteric site and directly inhibit fibrin from binding to the
receptor. The remainder of this thesis presents the properties and mechanisms
of the Glycoprotein IIb/llia receptor inhibitor drugs. Also, since Clopidogrel and
Aspirin are important treatments for patients presenting with Cardiovascular
Diseases, there is a brief discussion about the properties and mechanisms of the
two drugs.

- Chhajwani 42 -

Figure 15. Role of Abciximab, Tirofiban , and Eptifibatide in the Platelet
Aggregation Pathway

Occupied
Binding Site
GP lIb/ IlIa
Receptor Inhibitors

••,

Eptifibatide/
Tirofiban

Abciximab

Altered Conformation
State

r--------------------------------------------------------------------------------GP lib/Ilia receptor antagonists serve to inhibit the binding of the GP lib/lila receptor
ligands by blocking or altering the active binding site on the receptor. Abciximab
serves to alter the conformational state of the receptor. Tirofiban and Eptifibatide
serve to occupy the binding site and directly inhibit ligand binding. This receptor
blockade prevents ligands from binding to the GP lib/lila receptors, thereby
preventing platelet aggregation.
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VI. Abciximab
Abciximab is sold under the trade name ReoPro. Reopro is manufactured
by Centocor (a wholly own subsidiary of Johnson & Johnson) and
marketed/distributed by Eli Lilly and Company. Reopro was approved by the
Food and Drug Administration in 1994. In February of 1995 it was introduced to
the United States as an anti-platelet drug that served as a Glycoprotein lib/lila
receptor inhibitor. Abciximab was introduced as a monoclonal antibody that has
the ability to bind noncompetitively to GPllblllla receptors on platelets. Since the
GPllblllla receptors normally bind fibrinogen, Abciximab binding to the receptor
blocks the receptor-fibrinogen linkage and blocks the final pathway of platelet
aggregation (1994; Tamhane and Gurm 2008).

VI-A. Monoclonal Antibody Technology
The development of monoclonal antibody technology enabled researchers
to develop "magic bullets" that could target specific diseased states. These labmade antibodies confer a protection against specific antigens. Antibodies are
specific to one type of antigen, thus can offer great selectivity. These qualities
are what make antibodies important in treating specific diseases (Peterson
2005).
Initial engineering of antibodies allowed researchers to direct antibodies
against tumor cells of mice. Researchers were successful in inhibiting the growth
of these tumors by specifically "attacking" the antigens that created the tumors.
Next, it was essential to humanize these antibodies, so they could be used as
treatment with humans. This was done by utilizing the mouse antibodies already
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created and determining the similarities of the sequences between mouse and
human antibodies. Using recombinant technology, researchers were able to
create antibodies that would work within the human system (Peterson 2005).
Once a particular type of antibody has been classified, a special cell line
(hybridoma) is created that can produce the desired antibody. This insures that a
monoclonal antibody is produced in a pure form (Peterson 2005). Figure 16
outlines monoclonal antibody production.
The production of Abciximab is carried out in a hybridoma cell. Abciximab
is a part of the Fab fragment of the chimeric human-murine (mouse) monoclonal
antibody 7E3. The Fab fragment is the portion of the antibody that recognizes
antigens. Figure 17 outlines an antibody structure. Abciximab is produced by
continuous perfusion in the cell culture. The fragment is then purified by a
method of several steps that involve viral inactivation and removal procedures
(2005).
VI-B. Uses
Abciximab is used in particular settings. Abciximab is the favored antiplatelet drug in high risk acute coronary syndrome patients who are under going
a PCI procedure (Tamhane and Gurm 2008). Abciximab can be administered in
several ways. Abciximab can be infused via intracoronary or intravenous means
or it can be administered in a bolus form (all at once) along with other
anticoagulant agents. In clinical settings, both models are used by using an initial
bolus form and then infusion therapy concurrently with the procedure. Abciximab
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Figure 16. Monoclonal Antibody Production
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,---------------------------------------------------------------------------------,
The figure shows the production of a murine model monoclonal antibody. First, a mouse is
injected with a specific antigen, which causes the natural production of antibodies conferred
against that antigen. The cells that are naturally producing the antibodies are isolated from the
spleen and grown in culture. To create a pure antibody, a single cell colony is chosen and a
hybridoma cell line is created. The hybridoma cell line can then mass produce the antibodies.
Source: (Falkenberg 1998; Peterson 2005)

1 ______ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - _____________________________ 1
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Figure 17. Antibody Structure

Light Chain

Papain Cleavage Site

3-<
Heavy Chain

Antibodies are selective towards antigens on foreign particles and bacteria. As Figure 17
depicts, there several regions that make up an antibody. The dark purple and dark red
regions of the heavy and light chains are similar in all antibody structures. The variable
regions, in light purple and light red, are the regions which offer antigen selectivity. The
antigen fragment binding sites (Fab sites) are located at the terminal end of the structure
and are indicated by the green circles. The enzyme Papain digests the antibody at the site
denoted by the scissors. This cleavage creates the Fab Fragment.

1______________________________________________________________________________ _
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VII-D. Mechanism of Action

The mechanism of action for Tirofiban is different from that of Abciximab.
Tirofiban serves as a highly selective antagonist for the GP lib/lila receptor.
Tirofiban treatment results in competitive inhibition of fibrinogen and the von
Willebrand-mediated platelet aggregation on the GP lib/Ilia receptor. Tirofiban
binds to the receptor reversibly and occupies directly the binding site (the RGD
recognition site, which serves as the binding site for fibrinogen/vitronectin/and the
von Willebrand factor). Tirofiban does not cross react with any other receptors
(Winter and Juergens 2008).
The half life of Tirofiban in plasma is approximately 2 hours. Tirofiban has
a shorter platelet bound half-life (10-15 seconds). Tirofiban has a lower binding
affinity to the GP lib/lila receptor and rapidly disassociates. Tirofiban has an
equilibrium dissociation constant

(~)

of 15 nM. With a 3 fold higher

~

than

Abciximab, Tirofiban binds with a lower affinity to the substrate than Abciximab.
Within four hours after therapy has ended, Tirofiban is completely removed from
the receptors. Tirofiban exhibits great platelet inhibitory functions. Tirofiban is 8590% successful at inhibiting platelet aggregation by binding to the GP lib/lila
receptor (Winter and Juergens 2008).
VII-E. Side Effects

Adverse effects noted with Tirofiban usage are similar to the other platelet
aggregation inhibitor drugs. Excess bleeding is noted as a concern and steps
must be taken to prevent excessive blood loss. Unlike Abciximab, Tirofiban does
not increase likelihood of Thrombocytopenia (as compared to a Placebo).
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the receptor. Abciximab allows an anti-inflammatory response. Abciximab also
offers long term vessel healing and stability (2005; Tamhane and Gurm 2008).
Abciximab binds to the activated Mac-1 receptor found on leukocytes. The
Mac-1 receptor mediates leukocyte to platelet attachment. Abciximab serves a
similar role in the Mac-1 receptor mechanism as it does with the vitronectin
receptor. Abciximab blocks the Mac-1 receptor. Abciximab thereby disables the
ability of the Mac-1 receptor to mediate leukocyte to platelet attachment
(Tamhane and Gurm 2008).
VI-D. Clinical Trials
In order for the FDA to approve a particular drug, several clinical trials
need to be completed . These trials need to test the drug in several settings
versus a placebo. Abciximab has been tested in four Phase 3 clinical trials.
Phase 3 clinical trials are performed on a large number of patients and used to
see a definitive assessment on the effectives of the drug. The four trials of
Abciximab were EPIC, EPILOG, CAPTURE and EPILOG StenUEPISTENT.
Table 2 summarizes the Phase 3 clinical trials, which evaluated the effect of
Abciximab.
The EPIC trial conducted a controlled study in patients who had the
percutaneous transluminal coronary angioplasty and were at high risk for an
abrupt closure of the treated coronary vessel. There were three different groups:
patients treated with Abciximab bolus plus infusion for 12 hours, patients treated
with Abciximab bolus plus placebo infusion , and patients treated with placebo
bolus plus placebo infusion. All groups of patients received standard heparin and
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Table 2. Clinical Trials of Abciximab.

Trial
EPIC

Patient Type
Patients undergoing
percutaneous transluminal
coronary angioplasty (PTCA)
and were at risk for abrupt
closure of the treated coronary
vessel

EPILOG

Broad population of patients
undergoing PCI

CAPTURE

Patients with unstable angina
who have not responded well
to conventional medical
therapy; scheduled for PCI

EPILOG Stentl Broad population of patients
EPISTENT
undergoing PCI
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Methods Tested
1. Abciximab bolus plus
(Abciximab) infusion for 12
hours;
2. Abciximab bolus plus
placebo infusion for 12 hours;
3. Placebo bolus plus (placebo)
infusion for 12 hours.
1. Abciximab (both bolus and
infusion) plus standard-dose
heparin;
2. Abciximab (both bolus and
infusion) plus low-dose heparin;
3. Placebo plus standard-dose
heparin.
1. Abciximab bolus + infusion
for 18 to 24 hou rs before
procedure;
2. Placebo bolus + infusion for
18 to 24 hours before
procedure
(Heparin infusion used in both)
1. Conventional PTCA with
Abciximab + low does Heparin;
2. Primary intracoronary stent
placement with Abciximab +
low dose heparin;
3. Primary intracoronary stent
placement with Placebo +
standard dose heparin

X. Aspirin
Aspirin is commonly used anti-platelet agent. Aspirin is a household drug
used for a variety of ailments. The benefits of Aspirin in cardiovascular disease
are important because of the ability of Aspirin to mediate platelet aggregation.
The mechanism of action of Aspirin is carried out by the ability of Aspirin
to selectively and rapidly acetylate a serine residue in the in the cycloocygenase
active site for the enzyme prostaglandin-H synthase (COX) that causes
irreversible inhibition. The COX enzyme is responsible for prostaglandin and
thromboxane synthesis. Prostaglandin and thromboxane are involved in fat build
up and clot formation. There are two isoforms of COX, known as COX-1 and
COX-2. COX-1 is involved in the maintenance function of various tissues and is
termed the "house-keeping" isoform. COX-2, unlike COX-1, is undetectable in
normal tissues. COX-2 is referred to as the "inducible" isoform because it is
expressed heavily in areas of inflammatory stimulus. By acetylating a serine
residue, Aspirin is able to irreversibly inhibit COX-1 and is able to alter the
enzymatic activity of COX-2. (Bjorklund, Wallander et al. 2009).
It has been found that long term aspirin treatment inhibits platelet
aggregation by inhibiting the formation of a pro-aggregant prostanoid,
thromboxane A2. Thromboxane A2 is formed in platelets through the stimulation
of COX-1. By blocking formation of thromboxane A2, Aspirin produces an
inhibitory effect on clot formation and platelet aggregation. Since Aspirin is more
selective for inhibiting COX-1 than COX-2, even low-dose Aspirin is effective in
inhibiting platelet aggregation (Bjorklund, Wallander et al. 2009).
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aspirin treatment. The results showed that with Abciximab bolus plus infusion
treatment the primary endpoint (death, myocardial infarction, or urgent
intervention) was reduced by 350/0 in the first 48 hours and lasting up to 30 days

(1994; 2005).
The EPILOG trial conducted a controlled study in a broad group of
patients undergoing PCI excluding patients with myocardial infarction and
unstable angina who met the standards for the EPIC trial. There were three
different groups: a patient group that received a placebo and standard heparin
dose, a patient group that received Abciximab bolus plus infusion and standard
heparin dose, and a patient group that received Abciximab bolus plus infusion
and low does of heparin. The results showed that the primary endpoint (death or
myocardial infarction within 30 days) was observed less in patients undergoing
Abciximab treatment. The primary endpoint was observed in 4.2% of patients
undergoing Abciximab treatment with standard heparin; in 3.8% of patients
undergoing Abciximab treatment with low dose heparin; and in 9.1 % of patients
undergoing placebo treatment). The secondary end point (death, myocardial
infarction, or repeat intervention within 6 months) was also observed less in
patients undergoing Abciximab treatment. The secondary endpoint was observed
in 22.3%) of patients undergoing Abciximab treatment with standard heparin; in

22.80/0 of patients undergoing Abciximab treatment with low dose heparin; and in
25.8% undergoing placebo treatment. This study showed that Abciximab was
more beneficial than a placebo treatment (1997**; 2005).
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The EPISTENT trial did a control study in patients undergoing PCI. They
evaluated three different treatment strategies. One group of patients underwent
percutaneous transluminal coronary angioplasty (PTCA, no stent) with Abciximab
plus low dose heparin treatment. Another group tested underwent primary
intracoronary stent placement with Abciximab plus low dose heparin treatment.
The third group underwent primary intracoronary stent placement with placebo
and a standard dose of heparin treatment. The results showed that patients in
both stent and non-stent studies who underwent Abciximab treatment had a
reduction in primary endpoint results with relation to death, myocardial infarction
or urgent intervention Primary endpoint was observed in 5.30/0 of patients in the
Abciximab/stent group and in 6.9% of patients in the Abciximab/PTCA group.
Primary endpoint in the placebo/stent group was achieved in 10.8 % of patients.
The secondary end point (death, myocardial infarction, or repeat intervention
within 6 months) was observed less in patients undergoing Abciximab treatment.
Secondary endpoint was observed in 6.40/0 of patients in the Abciximab/stent
group and in 9.2% of patients in the Abciximab/PTCA group. Secondary endpoint
in the placebo/stent group was achieved in 12.1 % of patients. This study showed
that Abciximab treatment was more beneficial than a placebo treatment in both
stent and non-stent utilized procedures (1998; 2005).
The CAPTURE trial conducted a controlled study in patients who
presented with unstable angina that did not respond to conventional medical
therapy. A PCI procedure had been planned but not performed. The trial studied
cases in which the Abciximab administration started 18 to 24 hours prior to PCI
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procedure and continued one hour post procedure. The results showed that the
primary endpoint (death or myocardial infarction within 30 days) was observed
less in patients undergoing Abciximab treatment. Primary endpoint was observed
in 11.3% of patients undergoing Abciximab treatment and in 15.9%) of patients
undergoing placebo treatment. The secondary end point (death, myocardial
infarction, or repeat intervention within 6 months) was not significantly different.
Secondary endpoint was observed in 31 % of patients undergoing Abciximab
treatment and in 30.8% of patients undergoing placebo treatment. This study
showed that Abciximab was beneficial than a placebo treatment at the initial
stages in the CAPTURE trial. However, Abciximab treatment showed no
difference within 6 months (1997; 2005). Though death was listed as a primary
and secondary endpoint in most of the trials, high mortality rates were
uncommon (2005).
VI-E. Side Effects
A majority of side effects witnessed by administration of Abciximab are
related to its function as an anti-platelet agent. One of the main side effects is an
increased risk of bleeding. The most common type of bleeding noticed is a
gastrointestinal hemorrhage. A way to combat this issue is to use anticoagulant
agents such as heparin alongside Abciximab treatment. Another rare, but very
risky, side effect is thrombocytopenia, which results in dropping of blood platelet
counts. Most of the observed side effects are mild and do not hinder the potential
treatment. A treatment that transfuses platelets is adopted when the patient has
developed Thrombocytopenia (2005).
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In patients observed within EPIC, EPILOG, and CAPTURE trials, several
minor but uncomfortable side effects were noticed. Adverse events that occurred
in more than 100/0 of patients include hypertension (14.4% vs. 10.3% in placebo
patients); nausea (13.6% vs. 11.50/0 in placebo patients; and back pain (17.6%
vs. 13.7 % in placebo patients) (2005).

VII. Tirofiban
Tirofiban, a Glycoprotein Ilb/llia inhibitor, is sold under the trade name
Aggrastat. Aggrastat is manufactured/distributed/marketed by Merck Sharp and
Dohme. Tirofiban is considered a small-molecule inhibitor with a molecular
weight of 495 Da. Tirofiban is a tyrosine derived, non-peptide molecule that has a
high specificity to the GP lib/lila receptor integrin (Winter and Juergens 2008).

VII-A. Small Molecule Inhibitors
Being able to control protein to protein interactions is important in
pharmacology and in patient management. Antibody technology (as seen with
Abciximab) is very useful. Antibodies provide specificity to the target and are
stable in human serum. However, Antibodies are difficult to manufacture (since
they rely on living systems to be produced). Antibodies are also not cell
membrane permeable (because of the massive size). Small-molecule inhibitors
are providing means to alter the course of existing protein to protein interactions.
Once the targeted protein is understood, with both its structural and biophysical
properties studied, manufacturing of a particular small-molecule inhibitor as a
therapeutic agent becomes possible. Fortunately, the GP IIb/llia receptor is a
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highly studied protein, enabling synthesis of small-molecule inhibitors of the
GPllb/llla receptor (Arkin and Wells 2004).

VII-B. Development
Development of Tirofiban is different from Abciximab since Tirofiban is a
small molecule inhibitor. Tirofiban is derived from the RGD motif sequence that
binds to the Glycoprotein lib/lila receptor. This sequence is also present in
fibrinogen, von Willebrand factor and vitronectin. Initially, production of Tirofiban
was difficult due to enzymatic breakdown of peptide bonds within the molecule,
which resulted in an unstable molecule. After further research, Tirofiban was
synthesized using D-amino acids instead of a-amino acids. These conformational
changes made the molecule stronger. The new molecule lacked the vulnerable
peptide bonds enabling the molecule to stay in circulation longer (Winter and
Juergens 2008).

VII-C. Uses
Tirofiban is used in highly specific clinical settings. Similarly to Abciximab,
Tirofiban is used in patients with a ST-Segmented Elevation Myocardial Infarction
(STEMI). STEMI is an acute obstruction in an epicedial artery. Tirofiban is also
used in non-ST-segment elevation acute coronary syndromes. The surgical
procedure, PCI, is used as a management protocol to restore function in patients
who suffer from STEMI and non-ST segment elevation acute coronary
syndromes. Tirofiban is used in conjunction with aspirin and heparin. It has been
found that Tirofiban in a high-weight adjusted dose is most beneficial to patients
(van 't Hof and Valgimigli 2009).
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is also accompanied by a low-dose weight-adjusted heparin infusion (2005;
Tamhane and Gurm 2008).
VI-C. Mechanism of Action
Abciximab is a large 47615 Dalton (48 kDa) molecule. Abciximab blocks
access of ligands to the RGD-sequence binding site and secondary fibrinogen
binding site on the GPlib/lila receptor. Abciximab does not directly bind to the
RGD binding site; however, it acts as a noncompetitive inhibitor of the GP lib/lila
receptor by binding to an allosteric site (Tamhane and Gurm 2008). Abciximab
has an equilibrium dissociation constant (Kd) of 5 nM. A low Kd indicates that the
molecule binds with high affinity to the substrate. This high affinity allows it to
remain bound to the receptor with a half- life of 4 hours (for the platelet bound
drug) and disassociates slowly. The plasma half life is 10-30 minutes (for
unbound drug). The biological half life (amount of time the half of the drug is
removed from the entire system) is 12-24 hours (Kam and Egan 2002). With
appropriate dosage, Abciximab can achieve a greater than 800/0 inhibition of the
GP lib/Ilia receptor population (2005; Tamhane and Gurm 2008).
Unlike the other GP lib/Ilia receptor inhibitors (Tirofiban and Eptifibatide),
Abciximab can cross react with other receptor integrins not related to the platelet
aggregation pathway (Winter and Juergens 2008). Abciximab binds to the
vitronectin receptor

av~3,

which is located on the surface of endothelial and

vascular smooth muscle cells. The vitronectin receptor has roles in smooth
muscle migration and endothelial cell attachment to platelets. Abciximab blocks
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VIII. Eptifibatide
Eptifibatide, a Glycoprotein lib/lila inhibitor, is sold under the trade name
Integrilin. Integrilin is manufactured/distributed by COR Therapeutics. Eptifibatide
was produced after Abciximab. Similarly to Tirofiban , Eptifibatide was designed
to reduce the unintended complications arising from Abciximab. The main goal of
Eptifibatide synthesis was to produce an agent that could rapidly disassociate
from platelet bound GP lib/lila receptor. Eptifibatide is an agent that is reversible
and lowers the risk of bleeding. Eptifibatide is used in similar PCI cases as
Abciximab and Tirofiban (Scarborough 1999).

VIII-A. Development
The development of a novel GP lib/Ilia inhibitor drug began with
researching a wide range of snake viper venoms. These venoms contain
compounds known as disintegrins. Disintegrins are small proteins that serve as
antithrombotics and inhibit platelet aggregation. These small molecules contain
the RGD amino acid sequence. However, it was noted that these RGD
containing molecules also were able to cross reacted with other integrins (such
as the

av~3

integrin). After continual research, venom from the Sistrurus barbouri

pigmy rattlesnake, known as barbourin, a 73- amino acid disintegrin, was found
to contain a KGD (Iysine- glycine- aspartate) sequence. This sequence allowed
the small molecule to interact with the GP lib/lila receptor but not other integrins.
Barbourin provided a template for the construction of a synthetic peptide that
could be used clinically. Eptifibatide, a heptapeptide (7 peptides) cyclized by a
disulfide bridge, was created. Eptifibatide proves to be a potent, specific inhibitor
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with high affinity for the GP lib/lila receptor. Eptifibatide contains the modified
KGD peptide recognition (Scarborough 1999).
VIII-B. Mechanism of Action
The mechanism of action of Eptifibatide is similar to Tirofiban. Eptifibatide
acts as a small molecule inhibitor to block the binding of fibrinogen and the von
Willebrand factor to the GP lib/lila receptor on activated platelets. Effects of
Eptifibatide on inhibition of platelet aggregation can be seen within 15 minutes of
drug administration. Eptifibatide has a short half life and rate of elimination from
circulation in plasma of 1-2 hours. Eptifibatide has an equilibrium dissociation
constant (Kci) of 120 nM. With A significantly higher Kd than Abciximab,
Eptifibatide binds with a much lower affinity to the substrate than Abciximab.
Eptifibatide is able to act as a reversible agent (Scarborough 1999). The
biological half-life of Eptifibatide is 2-4 hours (Kam and Egan 2002).
VIII-C. Side Effects
Adverse effects, such as bleeding, are reduced because of the reversibility
and short platelet bound life of Eptifibatide. Also, thrombocytopenia is not
observed in greater proportions in patients undergoing Eptifibatide treatment vs.
Placebo treatment (Scarborough 1999).
IX. Clopidogrel
Clopidogrel is an oral agent with inhibitory properties of platelet
aggregation. Clopidogrel is used in patients who present with cardiovascular
risks and multiple co-morbid conditions such as stroke, myocardial infarction,
atherosclerosis (and other forms of coronary artery disease), peripheral vascular
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disease, and cerebrovascular diseases. Clopidogrel is manufactured and
marketed by three pharmaceutical companies. Clopidogrel was developed by
Sanofi Research teams in 1998. The well known trade name Plavix is marketed
by Bristol-Myers Squibb and Sanofi-Aventis. The trade name Clopilet is marketed
by Sun Pharmaceuticals. The trade name Ceruvin is marketed by Ranbaxy
Laboratories (Mullangi and Srinivas 2009).
The mechanism of action of Clopidogrel is to selectively bind to the
platelet surface on the adenylate cyclase coupled ADP receptors to block one of
the starting pathways of platelet aggregation. Clopidogrel allows for an
irreversible blockade of the ADP receptor, P2Y12. The P2Y 12 receptor is important
in platelet aggregation and in the cross linking of platelets by fibrin. The
clopidogrel molecule blocking the P2Y 12 receptor inhibits the preliminary
activation of the Glycoprotein Ilb/llia pathway. In order for Clopidogrel to be
activated, the drug requires catalyzation by the cytochrome P450 isozymes
(Mullangi and Srinivas 2009).
Clopidogrel is used as preventive medicine. Clopidogrel is taken daily by
at-risk patients who are taking remedies to reduce their risk of thrombus
formation leading to blocked arteries. For patients who are taking Clopidogrel as
a type of preventative treatment, the recommended dosage is 75 mg/day. The
inhibitory effects can be noticed after 2 hours of initial treatment and can last 3-7
days after oral treatment. If the medication is taken continually then the effects
are longer lasting (Mullangi and Srinivas 2009).
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Patients who are at risk for cardiovascular disease are usually also at risk
for gastrointestinal complications. Consideration needs to be made during
administration to account for the gastrointestinal adverse effects that are well
documented for Aspirin treatment. In efforts to mediate these complications,
health care providers should develop a plan to reduce dosage and length of
treatment. Health care providers should also avoid prescribing drugs with similar
adverse effects (Bjorklund, Wallander et al. 2009).

XI. Drug Comparisons
When considering which drug therapy to use in patients undergoing PCI
health care providers have a selection of GPI drugs that they can choose.
Abciximab is a chimeric monoclocal antibody. Tirofiban is a nonpeptide tyrosine
derivative. Eptifibatide is a cyclic heptapeptide. Each treatment varies in
molecular structure, active half-life, plasma half-life, receptor binding affinity,
method and duration of administration , and cost. Several studies have been
conducted to determine end-point outcome of patients undergoing the above
mentioned drugs. Table 3 outlines the differential properties of the three GPI
drugs.

XI-Ai. Abciximab/Tirofiban - source: (Gowda, Vacek et al. 2003)
A study conducted at the Mid America Heart Institute in Kansas City, MO
observed 228 patients (114 that received Abciximab and 114 that received
Tirofiban) who underwent treatment for unstable angina or myocardial infarction
between 1/98 and 12/99. Clinical parameters, such as equipment, techniques,
and decision for revascularization, were made by the attending physician.
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Table 3. Properties of GP lib/Ilia Receptor Inhibitors

Molecule Type

Size
Platelet Bound
Half life
Plasma Half- Life
Biological HalfLife
Mechanism of
receptor binding

Equilibrium
dissociation
constant (Kd)
Cost
(Approximate)

Abciximab
Monoclonal
Antibody; Fab
fragment of
Antibody
47615 Da
4 hours

Tirofiban
Small-molecule
inhibitor;
nonpeptide

Eptifibatide
Small-molecule
inhibitor; peptide

495 Da
10-15 seconds

10-15 minutes
12-24 hours

2 hours
2-4 hours

832 Da
Similar to
Tirofiban
1-2 hours
2-4 hours

Noncompetitive
inhibition; binds to
allosteric site; with
rapid onset; high
receptor affinity;
slow
disassociation
5nM

Competitive
inhibition;
reversibly binds to
orthosteric site;
rapid onset; low
receptor affinity;
rapid
disassociation
15 nM

Com petitive
inhibition;
reversibly binds to
orthosteric site;
rapid onset; low
receptor affinity;
rapid
disassociation
120 nM

$1500/ 12 hour
dose

$500/ 24 hour
dose

$500/ 12 hou r
dose
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In order to have a statistically valid test, it was pertinent to have nonsignificance in variation between the Abciximab and Tirofiban group in the
baseline characteristics of: age, gender, ejection fraction. It was also pertinent to
insure that the past medical histories of the patients were similar in relation to
diabetes, congestive heart failure, hypertension, atrial fibrillation,
cardiomyopathy, end stage renal disease, hyperlipidemia, occurrence of a
cerebrocavascular accident, occurrence of a transient ischemic attack, peptic
ulcer disease, or occurrence of prior coronary artery bypass graft
surgery/percutaneous transluminal coronary angioplasty. Smoking history, which
was one baseline factor, was significantly different between the patients who
where administered Tirofiban (34 smokers out of 114) and those that were
administered Abciximab (21 smokers out of 114). Distribution of diseased
vessels and which vessel was revascularized was similar in both groups. Table 4
shows which type of interventional treatment the patients underwent.
The results showed that no intracranial bleeds occurred in either group.
Length of stay was also similar to both groups (5 days for Abciximab and 4.2
days for Tirofiban). Post procedure complications such as death, myocardial
infarction, urgent revascularization, a cerebral vascular accident, transient
ischemic attack, occurrence of thrombocytopenia, GI bleed, or need for
immediate blood transfusion occurred at with a non-significant difference in both
groups. Table 5 shows the immediate post procedure complications observed.
There was no significance in difference between Tirofiban treatment and
Abciximab treatments immediately post procedure.
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Table 4. Type of Interventional Treatment in Mid America Heart Institute Study
Type of Treatment
None
PTCA
PTCA with Stent
CABG

Tirofiban
(N=114)
9.6%
1.8%
79.8%
9.6%

Abciximab
(N=114)
2.60/0
3.5%
92.1 %
2.60/0
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Table 5. Immediate Post Procedure Complications in Mid America Heart Institute
Study
Tirofiban
Immediate
(N=114)
Complication
1.8%
Death
Myocardial Infarction 1.8%
4.4%
Urgent
Revascularization
Cerebral Vascular
0
AccidenU Transient
Ischemic Attack
18%
Access site bleed
5.3%
Gastrointestinal
Bleed
1.8%
Required Blood
Transfusion
Thrombocytopenia
.90/0
**p Value = Non-significant for all

Abciximab
(N=114)
1.8%

0
.90/0
.90/0

170/0
2.6%
4.4%
1.8%
data points
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The results from the one year follow up data showed an event-free survival (no
death, myocardial infarction, or repeat-revascularization) trend favoring Tirofiban.
There was a 68% event-free survival in patients with Tirofiban treatment. There
was a 55% event-free survival in patients with Abciximab treatment. However,
the p-value showed non- significance with the data points comparing Tirofiban
and Abciximab in event-free survival one year post procedure. Table 6 shows
several factors studied at the one-year follow up data.
The study also considered whether the intervention was performed in an elective
or emergent manner. Emergent intervention was described as having a
procedure performed immediately after a patient made a trip to the emergency
department for an acute attack. All other patients were considered elective.
There was non-significance in the difference between which treatment (Tirofiban
or Abciximab) was used between elective or emergent patients. The results
showed that patients who were administered Abciximab in an emergent setting
had a greater chance of no-repeat-revascularization than the patients who were
administered Tirofiban. 100% of patients administered Abciximab were free from
repeat-revascularization versus 81 % of the Tirofiban group. The results showed
that patients who were administered Tirofiban in an elective setting were offered
a greater chance of no-repeat-revascularization than the patients who were
administered Abciximab. 930/0 of patients administered Tirofiban were free from
repeat-revascularization vs. 77% of the Abciximab group. The cost of each
administration varies greatly. Abciximab is approximately $1500 for a 12-hour
dose and Tirofiban is approximately $500 for a 24-hour dose.
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Table 6. One Year Post Procedure Complications in Mid America Heart Institute
Study
Post One year
Tirofiban
Abciximab
(N=114)
Complication
(N=114)
1.8%
Death
3.60/0
Myocardial Infarction
1.80/0
0
9.6%
Revascu la rization
130/0
8.7%
In-stent Restenosis
4.30/0
(at prior damage site)
.9%
3.6%
Different Lesion
8.7%
21.9%
Hospitalization Cardiovascular
Issues
(p Value = .01)
7.9%
Hospitalization- non
15.80/0
Cardiovascular
Issues
12.2%
25.4%
Composite of Death,
Myocardial Infarction,
or Cardiovascular
Issues Hospitalization
(p Value = .02)
**p Value = Non-significant for all data points (except those noted)
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The study concluded that the outcome of each drug therapy was not
significantly different. The authors of the Kansas City study believe that Tirofiban
was preferred for initial administration for patients presenting with acute coronary
syndromes . The authors believed that Abciximab was preferred by intervention
cardiologists in catheterization laboratory use.

XI-Aii. AbciximablTirofiban - TARGET trial (Topol, Moliterno et al. 2001)
The TARGET trial was conducted in 149 hospitals in 18 countries with
4809 patients. The trial considered patients who were administered Tirofiban or
Abciximab before undergoing PCI with stent treatment. The primary end point
was death , nonfatal myocardial infarction, or urgent target-vessel
revascularization within 30 days.
The results showed that the primary endpoint occurred more in the
Tirofiban group (7.60/0 of the total 2398 patients experienced one of the primary
end point events) than the Abciximab group (6% of the total 2411 patients
experienced one of the primary end point events). However, Abciximab therapy
resulted in higher minor bleeding episodes (4.30/0 vs. 1.8% with Tirofiban therapy,
p value- significant at .05 confidence level at 950/0 significance level). Thus it was
shown that Tirofiban offered less protection from major ischemic events than
Abciximab did in a 30 day period .

XI-B. Abciximab/Eptifibatide- EVA-AMI Trial (Zeymer and Wienbergen 2007)
The EVA-AMI trial was conducted with 427 random STEMI patients who
underwent PCI with Eptifibatide or Abciximab treatment. It was shown that
eptifibatide was found to be non-inferior in comparison with Abciximab when
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looking at the primary endpoint of complete ST resolution 1 hour after the PCI
procedure. Also, no significance was found in differences in in-hospital mortality
or major bleeding events.

XI-C. Abciximab/Eptifibatide/Tirofiban - (De Luca, Ucci et al. 2009)
A group of physicians from Italy conducted a meta analysis of the
randomized trials. The physicians considered trials that compared Abciximab
treatment against the small molecule inhibitors (Eptifibatide and Tirofiban) in
primary angioplasty procedures conducted on patients who presented with STsegment elevated myocardial infarction. This meta analysis aimed to study the
outcomes following the differential treatments. They screened 2297 patient files
from MEDLINE and CENTRAL (electronic databases) and in scientific journals
(Circulation, Journal of the American College of Cardiology, European Heart
Journal, and American Journal of Cardiology) listed from 01/99 to 10/0B. They
deemed the primary endpoint to be mortality within 30 days. They deemed the
secondary endpoint to be reinfarction within 30 days, thrombolysis in myocardial
infarction (TIMI) within 30 days (ability to restore flow to grade 3), or ST-segment
resolution.
The study found 10B2 patients undergoing Abciximab versus 1115
undergoing small molecule inhibitor treatment,. It was found that in analysis of
both the primary and secondary end points, Abciximab offered similar results to
the small molecule inhibitors. The results have been summarized from the study
in Table 7. The study also did several statistical tests to validate the results from
the different trials.
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Table 7. Outcomes from Meta Analysis of Abciximab and Small Molecule
Inhibitors (Tirofiban/Eptifibatide)

Primary Endpoint
Mortality within 30 days
Secondary Endpoint
Reinfarction
Secondary Endpoint
TIMI
Secondary Endpoint
ST-segment resolution
Major Bleeding Complications

Abciximab
N= 1082
2.20/0

Tirofiban/Eptifibatide
N= 1115
2.0%

1.2%

1.2%

89.8%

89.1 %

67.80/0

68.2%

1.3%

1.90/0
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XII. Discussion
In order to fully understand a physiological process, there are many
biochemical and clinical aspects to be considered . This thesis presents the
clinical portion of the hemostatic system by discussing cardiovascular diseases,
specifically coronary artery diseases and how the potential treatments affect
individuals. This thesis also discusses the biochemical interactions of the
hemostatic system during platelet aggregation , coagulation, and fibrinolysis that
ultimately cause the clinical manifestations.
When choosing the best course of treatment for a patient, a physician has
several choices. As seen by the studies presented in this thesis, often times the
choices vary only slightly in outcome. In April 2009, the author of this thesis
conducted an interview with a local Knoxville physician, Dr. Stuart Bresee. Dr.
Bresee serves as the Chief of Cardiology at the University of Tennessee
Graduate School of Medicine. He is also on staff at the UT Medical Center
University Cardiology group. As a Cardiologist, Dr. Bresee was able to offer
tremendous amounts of clinical insight concerning the GP lib/lila inhibitor drugs.
Dr. Bresee believed Abciximab to be a prime contender for one of the
most effective drugs of its kind. He noted that nationally, Abciximab is used over
other similar drugs. However, at his Knoxville practice, Eptifibatide is used more
often due to cost. He stated that the clinical trials that he and his colleagues had
studied indicated that Abciximab and Eptifibatide provoke similar results. Thus, to
be more cost efficient, University Cardiology mainly uses Eptifibatide. The side
effects of any of the anti-platelet drugs that Dr. Bresee encounters are minimal
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and the risk of the patient potentially displaying signs of the side effects are not
solely enough reason to prevent administration of the drugs.
XIII. Conclusion
According to the trials presented, it was noted that Abciximab does not
provide superior treatment for patients undergoing percutaneous coronary
intervention over its small molecule inhibitor counterparts, Tirofiban and
Eptifibatide. Thus, physician preference and exposure to treatments highly
influences which treatment type is actually used.
The study of pharmacology is continually evolving and producing novel
substances that are more effective than their predecessors. The future of
research in anti-platelet treatment relies on advanced findings, both clinical and
biochemical. In order to combat some of the clinical side effects of the existing
drugs, researchers are continually searching for novel GP Ilb/liia receptor
inhibitor drugs. Progress is being made towards finding effective inhibitors that
have a lower affinity for the receptor. This lower affinity could result in reduced
bleeding complications. Clinical trials that consider dosage and duration of
treatment are providing valuable insight into finding the most effective treatment
for patients.
Preventative measures to combat cardiovascular diseases need to be
taken in order to solve the underlying problem. Risk factors such as smoking,
hypertension, and obesity are modifiable. Groups such as the World Health
Organization and the American Heart Association are educating citizens of the
dangers of unhealthy lifestyles. However, these organizations should also take
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part in the actual progress towards changing modifiable risk factors. Hopefully,
with continual education and outlets for action, individuals will chose to modify
their lifestyle.
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